<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758069</url>
  </required_header>
  <id_info>
    <org_study_id>0431-045</org_study_id>
    <secondary_id>MK0431-045</secondary_id>
    <secondary_id>2008_026</secondary_id>
    <nct_id>NCT00758069</nct_id>
  </id_info>
  <brief_title>Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)</brief_title>
  <official_title>Phase II Study on Sitagliptin -Assessment of Glucose-lowering Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with
      Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 3, 2005</start_date>
  <completion_date type="Actual">February 13, 2006</completion_date>
  <primary_completion_date type="Actual">February 13, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 24-hour Weighted Mean Plasma Glucose</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change from baseline at Week 4 is defined as 24-hour weighted mean glucose (24hr-WMG) at Week 4 minus 24hr-WMG at Week 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Glucose</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change from baseline at Week 4 is defined as fasting plasma glucose at Week 4 minus fasting plasma glucose at Week 0.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 50 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin phosphate</intervention_name>
    <description>100 mg once daily (QD), taken orally for 4 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>MK0431</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo tablet, QD, taken orally for 4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Sitagliptin</intervention_name>
    <description>50 mg twice daily (BID), taken orally for 4 weeks</description>
    <arm_group_label>3</arm_group_label>
    <other_name>MK0431</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients Have Type 2 Diabetes Mellitus On Diet/Exercise Therapy

        Exclusion Criteria:

          -  Patients Have Type 1 Diabetes Mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <reference>
    <citation>Nonaka K, Tsubouchi H, Okuyama K, Fukao Y, Johnson-Levonas AO, Amatruda JM. Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res. 2009 Mar;41(3):232-7. doi: 10.1055/s-0028-1100413. Epub 2009 Feb 27.</citation>
    <PMID>19253204</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2008</study_first_submitted>
  <study_first_submitted_qc>September 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <results_first_submitted>August 17, 2009</results_first_submitted>
  <results_first_submitted_qc>September 24, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2009</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase II.
First patient in: 31 July 2005. Last patient, last visit: 13 February 2006.
The study was conducted at 8 centers in Japan.</recruitment_details>
      <pre_assignment_details>Patients 20-69 years of age with type 2 diabetes mellitus and inadequate glycemic control (HbA1c â‰¥6.5% and &lt;10% at Week -2) were eligible for randomization following at least 8 weeks of diet/exercise and antihyperglycemic agent (AHA) wash-off (for patients previously on an AHA), including a 2-week placebo run-in.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin 100 mg QD</title>
          <description>The Sitagliptin 100 mg QD group includes data from all patients randomized to receive treatment with sitagliptin 100 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin 50 mg BID</title>
          <description>The Sitagliptin 50 mg BID group includes data from all patients randomized to receive treatment with sitagliptin 50 mg orally twice daily (BID=twice daily).</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>The Placebo group includes data from all patients randomized to receive treatment with matching placebo orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27">Study enrolled slightly more than the target of N=20</participants>
                <participants group_id="P2" count="25">Study enrolled slightly more than the target of N=20</participants>
                <participants group_id="P3" count="28">Study enrolled slightly more than the target of N=20</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin 100 mg QD</title>
          <description>The Sitagliptin 100 mg QD group includes data from all patients randomized to receive treatment with sitagliptin 100 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin 50 mg BID</title>
          <description>The Sitagliptin 50 mg BID group includes data from all patients randomized to receive treatment with sitagliptin 50 mg orally twice daily (BID=twice daily).</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>The Placebo group includes data from all patients randomized to receive treatment with matching placebo orally.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="8.9"/>
                    <measurement group_id="B2" value="56.1" spread="8.9"/>
                    <measurement group_id="B3" value="53.6" spread="10.3"/>
                    <measurement group_id="B4" value="54.6" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24-hour weighted mean plasma glucose (24hr-WMG)</title>
          <description>The 24hr-WMG is the weighted mean of the blood glucose weighted by the intervals between time points for a day [i.e. the area under curve in glucoseâ€“time profile through 24-hours (AUC0-24 hr) divided by 24].</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195.0" spread="55.6"/>
                    <measurement group_id="B2" value="188.9" spread="46.6"/>
                    <measurement group_id="B3" value="195.4" spread="46.2"/>
                    <measurement group_id="B4" value="193.2" spread="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158.6" spread="41.0"/>
                    <measurement group_id="B2" value="156.4" spread="41.3"/>
                    <measurement group_id="B3" value="164.1" spread="36.9"/>
                    <measurement group_id="B4" value="159.9" spread="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 24-hour Weighted Mean Plasma Glucose</title>
        <description>Change from baseline at Week 4 is defined as 24-hour weighted mean glucose (24hr-WMG) at Week 4 minus 24hr-WMG at Week 0.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>The Per Protocol population included patients with baseline and Week 4 (i.e., final primary timepoint) values for this outcome and excluded patients who met predefined criteria for protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg QD</title>
            <description>The Sitagliptin 100 mg QD group includes data from all patients randomized to receive treatment with sitagliptin 100 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 50 mg BID</title>
            <description>The Sitagliptin 50 mg BID group includes data from all patients randomized to receive treatment with sitagliptin 50 mg orally twice daily (BID=twice daily).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>The Placebo group includes data from all patients randomized to receive treatment with matching placebo orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-hour Weighted Mean Plasma Glucose</title>
          <description>Change from baseline at Week 4 is defined as 24-hour weighted mean glucose (24hr-WMG) at Week 4 minus 24hr-WMG at Week 0.</description>
          <population>The Per Protocol population included patients with baseline and Week 4 (i.e., final primary timepoint) values for this outcome and excluded patients who met predefined criteria for protocol violations.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.9" lower_limit="-40.9" upper_limit="28.9"/>
                    <measurement group_id="O2" value="-28.6" lower_limit="-34.7" upper_limit="22.4"/>
                    <measurement group_id="O3" value="-9.0" lower_limit="-14.8" upper_limit="-3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment among the pairwise comparisons of sitagliptin against placebo</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment as a factor and baseline value as a covariate was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-25.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-34.2</ci_lower_limit>
            <ci_upper_limit>-17.5</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment as a factor and baseline value as a covariate was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment among the pairwise comparisons of sitagliptin against placebo</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment as a factor and baseline value as a covariate was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-19.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-28.0</ci_lower_limit>
            <ci_upper_limit>-11.1</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment as a factor and baseline value as a covariate was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Glucose</title>
        <description>Change from baseline at Week 4 is defined as fasting plasma glucose at Week 4 minus fasting plasma glucose at Week 0.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>The Per Protocol population included patients with baseline and Week 4 (i.e., final primary timepoint) values for this outcome and excluded patients who met predefined criteria for protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg QD</title>
            <description>The Sitagliptin 100 mg QD group includes data from all patients randomized to receive treatment with sitagliptin 100 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 50 mg BID</title>
            <description>The Sitagliptin 50 mg BID group includes data from all patients randomized to receive treatment with sitagliptin 50 mg orally twice daily (BID=twice daily).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>The Placebo group includes data from all patients randomized to receive treatment with matching placebo orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Glucose</title>
          <description>Change from baseline at Week 4 is defined as fasting plasma glucose at Week 4 minus fasting plasma glucose at Week 0.</description>
          <population>The Per Protocol population included patients with baseline and Week 4 (i.e., final primary timepoint) values for this outcome and excluded patients who met predefined criteria for protocol violations.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.3" lower_limit="-27.7" upper_limit="17.0"/>
                    <measurement group_id="O2" value="-16.0" lower_limit="-21.4" upper_limit="10.6"/>
                    <measurement group_id="O3" value="-3.1" lower_limit="-8.2" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment among the pairwise comparisons of sitagliptin against placebo</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment as a factor and baseline value as a covariate was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-19.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-26.6</ci_lower_limit>
            <ci_upper_limit>-11.9</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment as a factor and baseline value as a covariate was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment among the pairwise comparisons of sitagliptin against placebo</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment as a factor and baseline value as a covariate was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-12.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-20.4</ci_lower_limit>
            <ci_upper_limit>-5.4</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment as a factor and baseline value as a covariate was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin 100 mg QD</title>
          <description>The Sitagliptin 100 mg QD group includes data from all patients randomized to receive treatment with sitagliptin 100 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin 50 mg BID</title>
          <description>The Sitagliptin 50 mg BID group includes data from all patients randomized to receive treatment with sitagliptin 50 mg orally twice daily (BID=twice daily).</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>The Placebo group includes data from all patients randomized to receive treatment with matching placebo orally.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="2"/>
                <counts group_id="E3" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Reported overdoses, regardless of association with reported adverse events, were considered as serious adverse events in this study. The patients for whom the event of overdose was reported had no concomitant AEs with the overdose.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

